Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL)

NCT00003215 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00003215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL)
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Completed
Start date
April 30, 1997
Completion date
March 31, 2004
Enrollment
400 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma